Drug Approval | December 26, 2025
Japan nod to Dupixent for children with severe asthma
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Full approval will depend on verification of clinical benefit in a confirmatory trial
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Growing patent filings and tier-2 innovators reflect expanding national research base
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
Subscribe To Our Newsletter & Stay Updated
